Celebrex combats skin cancer in vulnerable group

Anti-inflammatory drug limits tumors in patients with hereditary condition

The inflammation-fighting drug celecoxib prevents some outbreaks of skin cancer in people genetically predisposed to developing the malignancy, scientists report in the January Cancer Prevention Research.

People with a rare hereditary condition called Gorlin syndrome develop hundreds or even thousands of basal cell carcinomas in a lifetime.